Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial

By M. Valgimigli, G. Campo, M. Monti, P. Vranckx, G. Percoco, C. Tumscitz, F. Castriota, F. Colombo, M. Tebaldi, G. Fucà and 10 more. Circulation, 2012

627 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/2a64a11c2aec096a45ce7a911b95ff790c1b79a3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. P. O'Gara
2. Jose Luis Zamorano
3. M. Mack
4. L. Fleisher
5. Stephan Windecker

Citations in the corpus

• [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, methodology): “The PROlonging Dual antiplatelet treatment after Grading stent-induced intimal hYperplasia (PRODIGY) trial randomized 2013 patients [101] to 6 or 24 months of DAPT (ASA + clopidogrel) and to one of four stent types (a four-byTicagrelor MD (90 mg b.”
• 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, methodology): “The impetus for this focused update review is 11 studies (16-27) of patients treated with coronary stent”
• 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, background): “, 2012 (7) 22438530 Aim: To evaluate the impact of up 6 or 24 mo DAPT after BMS or DES”